Exhibit 10.5
ACM ARRT J LLC
c/o Atalaya Capital Management LP
One Rockefeller Center
32nd Floor
New York, NY 10020
March 18, 2024
VIA E-MAIL
aw@aeonbiopharma.com |
AEON Biopharma, Inc. 5 Park Plaza, Suite 1750 Irvine, California 92614 Email: aw@aeonbiopharma.com Attention: Chief Legal Officer |
Re: | Agreement (the “Agreement”) by and Among AEON Biopharma, Inc., a Delaware corporation (f/k/a Priveterra Acquisition Corp.), a Delaware corporation (“Counterparty”), AEON Biopharma Sub, Inc. (f/k/a AEON Biopharma, Inc.), a Delaware corporation (“Target”), and ACM ARRT J LLC (“Seller,” “we,” “us,” and “our”), to terminate the Forward Purchase Agreement dated as of June 29, 2023 (the “Forward Purchase Agreement”) |
To the above-referenced party:
[Signature Page Follows]
This Agreement was provided in compliance with the notice provisions and requirements of the Forward Purchase Agreement.
By: /s/ Drew Phillips__________________
Name: Drew Phillips
Title: Authorized Signatory
Agreed:
AEON BIOPHARMA, INC.
By: /s/ Marc Forth________________________
Name: Marc Forth
Title: President and Chief Executive Officer
AEON Biopharma Sub, Inc.
By: /s/ Marc Forth________________________
Name: Marc Forth
Title: Chief Executive Officer
With a copy to:
DLA Piper LLP (US)
555 Mission Street
Suite 2400
San Francisco, CA 94105
Attention: Jeffrey C. Selman
Email: jeffrey.selman@us.dlapiper.com